{"id":"tp-35195","type":"article-newspaper","title":"Zentalis Pharmaceuticals, Inc. Shares Rise After Trial Data Release","author":"Enna Lee","publisher":"TOKENPOST Inc.","url":"https://www.tokenpost.com/news/investing/35195","datePublished":"2026-10-20T01:46:12.000Z","dateModified":"2026-10-20T01:46:12.000Z","language":"en","abstract":"Median overall survival was 15.8 months for 48 patients whose tumors tested positive for Cyclin E1, versus 7.5 months for 46 who tested negative.","section":"Investing","references":[]}